Preparation of Hyaluronic acid-Aloevera Nanoparticles for Sustained Delivery of Doxycycline

علوم و تکنولوژی پلیمر

Mojdeh Sadat Mirshafiei¹  Soheil Boddohi¹ 

[1] Department of Biomedical Engineering, Faculty of Chemical Engineering, Tarbiat Modares University, P.O. Box: 14115-114, Tehran, Iran;

关键词: nanoparticles;    hyaluronic acid;    aloevera;    doxycycline;    sustained release;   

DOI  :  10.22063/jipst.2019.1620

来源: DOAJ

【 摘 要 】

Hypothesis: In this work, hyaluronic acid-aloevera (HA-AV) nanoparticles were prepared by nanoprecipitation method. Both HA and AV have shown great biocompatibility potential as antibacterial agents. Also chemical crosslinking of these two materials by esterification reaction could change stability and biodegradability. Doxycycline was selected as a drug model and encapsulated by HA-AV nanoparticles. Methods: Aloevera powder was prepared from the plant leaf and characterized by FTIR and NMR. The synthesis of HA-AV was carried out through esterification reaction. Size and shape of nanoparticles were measured by dynamic light scattering (DLS) and scanning electron microscopy (SEM). Anti-bacterial test was obtained against Staphylococcus aureus and Escherichia coli bacteria and also minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were measured.Findings: Average size of each particle before and after drug loading was about 118 nm and 171 nm, respectively. Doxycycline with an optimum concentration of 200 µg/mL was loaded, and drug loading content of 5.43% and drug loading efficiency of 40.14% were obtained. The sustained release profile showed 93.4% release during 16 days in PBS buffer solution. The results showed that the nanocarriers affected on both bacteria but the growth inhibitory loop was greater in Staphylococcus aureus. The cell viability test of nanocarriers was performed on NIH3T3 cell line by MTT assay method and nanoparticles containing 10 μg/mL of drug were selected as an appropriate concentration. Overall, this study has demonstrated that HA-AV nanocarriers can potentially be suitable for controlled release of doxycycline as a therapeutic agent for treatment of infectious diseases.

【 授权许可】

Unknown